Hepatitis B or C serologies consistent with past or current infectionsXx_NEWLINE_xXSevere infections within 4 weeks prior to randomization, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXSevere infections within 4 weeks prior to randomization including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXKnown active infectionsXx_NEWLINE_xXNo active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)Xx_NEWLINE_xXSevere infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPatients must not have severe infections within 28 days prior to registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPatients must not have severe infections within 28 days prior to step 1 registration, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXPatients currently being treated for severe infections or who are recovering from major surgery or other intercurrent illnesses are ineligible until recovery is deemed complete by the investigatorXx_NEWLINE_xXSubjects with uncontrolled serious infections or a life-threatening illness (unrelated to tumor)Xx_NEWLINE_xXPatients with clinically significant active infectionsXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illnesses that are uncontrolledXx_NEWLINE_xXUse of antibiotics to treat chronic infections within 28 days prior to first doseXx_NEWLINE_xXFungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 monthXx_NEWLINE_xXActive systemic infections requiring antibioticsXx_NEWLINE_xXPoor medical risk because of other conditions such as uncontrolled systemic diseases, active uncontrolled infections, or comorbidities that may put the patient at risk of not being able to complete at least 2 cycles of treatment.Xx_NEWLINE_xXActive clinically serious infections or other serious uncontrolled medical conditionsXx_NEWLINE_xXAny other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections etc.)Xx_NEWLINE_xXActive, known, clinically serious infections within the 14 days prior to first dose of investigational productXx_NEWLINE_xXActive bacterial infections.Xx_NEWLINE_xXUncontrolled infectionsXx_NEWLINE_xXParticipants who have any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXNo active serious infections or other conditions precluding chemotherapyXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).Xx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the study or compromise compliance with the protocol (e.g. chronic pancreatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.)Xx_NEWLINE_xXPatients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapyXx_NEWLINE_xXActive viral or bacterial infections: this includes any infections that are being actively treated even if the signs and symptoms appear to have resolved. Courses of antibiotics or anti-viral treatment should be completed before the patient is enrolledXx_NEWLINE_xXActive hepatitis viral infectionsXx_NEWLINE_xXActive serious infections not controlled by antibioticsXx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infectionsXx_NEWLINE_xXHistory of ocular events related to keratitis or corneal disorders, or any current ongoing active ocular infections.Xx_NEWLINE_xXPatients who have an active infection requiring systemic therapy are not eligible, except for uncomplicated urinary tract infectionsXx_NEWLINE_xXSevere infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXMust have no ongoing active, uncontrolled infections (afebrile for > 48 hours off antibiotics)Xx_NEWLINE_xXPatients with active bacterial infections with systemic manifestations (malaise, fever, leukocytosis) are not eligible until completion of appropriate therapy. Patients taking low-dose antibiotics for biliary obstruction are exempted from this exclusion criterion.Xx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXAny evidence of serious active infections; any infections being treated must complete antibiotic therapy at least 7 days before planned first dose.Xx_NEWLINE_xXHave active (acute or chronic) or uncontrolled severe infectionsXx_NEWLINE_xXSerious illnesses, e.g., serious infections requiring antibioticsXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)Xx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active or uncompensated major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXChronic infections (e.g., hepatitis B or C, tuberculosis)Xx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXRepeated infections requiring oral or i.v. antibioticsXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illness that are uncontrolled or the control of which may be jeopardized by this therapy.Xx_NEWLINE_xXPatient with active, uncontrolled infections (patients must be afebrile for > 48 hours off antibiotics).Xx_NEWLINE_xXActive systemic infections requiring anti-infective treatment, coagulation disorders or any other active major medical illnesses.Xx_NEWLINE_xXActive or fungal infections requiring systemic treatment within 7 days prior to screeningXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the study or compromise compliance with the protocol (e.g. chronic pancreatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.)Xx_NEWLINE_xXUncontrolled active systemic infectionsXx_NEWLINE_xXSevere infections within 4 weeks prior to enrollment;Xx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections requiring anti-infective treatment, coagulation disorders, or any other active major medical illnesses of the cardiovascular, respiratory or immune systemXx_NEWLINE_xXPatients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must have been adequately treated for at least 2 weeks before study entry; subjects with bacteremia must have documented negative blood cultures prior to study entryXx_NEWLINE_xXActive infectionsXx_NEWLINE_xXActive systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system. Principal investigator (PI) or his/her designee shall make the final determination regarding appropriateness of enrollment.Xx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXPatients with active infections. The principal investigator (PI) is the final arbiter of the eligibility;Xx_NEWLINE_xXPatients with other uncontrolled infections: For bacterial infections, patients must be receiving therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.Xx_NEWLINE_xXActive systemic infections requiring anti-infective treatment, coagulation disorders or any other active or uncompensated major medical illnessesXx_NEWLINE_xXPatients with any active and uncontrolled infections (such as bacterial, fungal, and new or reactivated viral infections)Xx_NEWLINE_xXAcute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 14 days prior to randomizationXx_NEWLINE_xXActive serious infections in particular if requiring systemic antibiotic or antimicrobial therapyXx_NEWLINE_xXSevere infections within 4 weeks prior to start of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia.Xx_NEWLINE_xXInfections such as pneumonia or wound infections that would preclude protocol therapy.Xx_NEWLINE_xXUncontrolled infections.Xx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections requiring anti-infective treatment, coagulation disorders or any other active or uncompensated major medical illnessesXx_NEWLINE_xXPatients with viral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use are ineligibleXx_NEWLINE_xXAcute or chronic infections requiring systemic therapy, including, among others:Xx_NEWLINE_xXSystemic rheumatic or autoimmune diseases or acute or chronic infectionsXx_NEWLINE_xXSevere infections within 4 weeks prior to the first study treatment, including but not limited to hospitalization for complications of infection, bacteremia or severe pneumoniaXx_NEWLINE_xXFungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 monthXx_NEWLINE_xXLife-threatening visceral disease or other severe concurrent disease that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXNo uncontrolled infections;Xx_NEWLINE_xXSevere infections within 4 weeks prior to study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXNo uncontrolled infections;Xx_NEWLINE_xXOther active infections aside from hepatitisXx_NEWLINE_xXPresence of any serious illnesses, serious medical conditions, serious medical history, active bacterial or viral infections including hepatitis B or C, or known to be HIV positive.Xx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Uncontrolled infection; active, clinically serious infections (> CTCAE grade 2)Xx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXNo active infectionsXx_NEWLINE_xXPatients with active infections; the principal investigator (PI) is the final arbiter of the eligibilityXx_NEWLINE_xXSevere infections ? 4 weeks prior to enrolment in the study as well as active, uncontrolled bacterial, viral or fungal infections requiring systemic treatment.Xx_NEWLINE_xXAny concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate subject participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).Xx_NEWLINE_xXActive infections within 48 hours of study entryXx_NEWLINE_xXActive uncontrolled acute infectionsXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks and contraindicate patient’s participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXActive uncontrolled systemic infections (defined as infections causing fevers and infections requiring intravenous antibiotics when the intravenous antibiotics have been administered for less than 72 hours); active coagulation disorders or other major uncontrolled medical illnesses of the cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or immune system; history of myocardial infarction; history of ventricular tachycardia or ventricular fibrillation; active cardiac arrhythmias (active atrial fibrillation is not allowed, but resolved atrial fibrillation is allowed); active obstructive or restrictive pulmonary disease; or active autoimmune diseases such as rheumatoid arthritisXx_NEWLINE_xXSubjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)Xx_NEWLINE_xXPatients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatmentXx_NEWLINE_xXEvidence of active infections =< 7 days prior to initiation of study drug therapy (does not apply to viral infections that are presumed to be associated with the underlying tumor type required for study entry)Xx_NEWLINE_xXActive uncontrolled bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapyXx_NEWLINE_xXSerious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligibleXx_NEWLINE_xXSevere infections within 4 weeks of first study treatment including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXKnown active infectionsXx_NEWLINE_xXThe presence of any other concurrent severe and/or uncontrolled medical condition that would, in the investigator or treating physician’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol; this includes uncontrolled infections that could potentially be exacerbated by anti-neoplastic treatment, active untreated or uncontrolled fungal bacterial or viral infections, etcXx_NEWLINE_xXCELL PROCUREMENT: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-respiratory syncytial virus (RSV), isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excludedXx_NEWLINE_xXLYMPHODEPLETION: Patients who are on treatment for other active uncontrolled infections (not referenced above) with resolution of signs/symptoms are not excluded; non-influenza, non-RSV, isolated upper respiratory infections are not excluded; other active uncontrolled infections will be excludedXx_NEWLINE_xXSignificant acute or chronic infections requiring systemic therapyXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXPatients with active infections; the principal investigator (PI) is the final arbiter of the eligibilityXx_NEWLINE_xXActive, clinically serious infections or other serious uncontrolled medical conditionsXx_NEWLINE_xXActive serious infections in particular if requiring systemic antibiotic or antimicrobial therapyXx_NEWLINE_xXAbsence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.Xx_NEWLINE_xXActive uncontrolled infection; infections controlled on concurrent anti-microbial agents are acceptable, and anti-microbial prophylaxis per institutional guidelines is acceptableXx_NEWLINE_xXUncontrolled infectionsXx_NEWLINE_xXActive systemic infections (for e.g.: requiring anti-infective treatment), coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, severe obstructive or restrictive pulmonary disease; patients with abnormal pulmonary function tests but stable obstructive or restrictive pulmonary disease may be eligibleXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXAcute, severe infection (e.g., sepsis and opportunistic infections), or active, chronic or persistent infection that might worsen with immunosuppressive treatment (e.g., herpes zoster).Xx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXPatient with known active herpes simplex virus infections (prior uncomplicated oral herpes simplex virus [HSV] lesions are not an exclusion), prior complications from HSV infections such as encephalitis, or who require systemic antiviral therapy at the time of study enrollment should be excludedXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXNot have active, uncontrolled infectionsXx_NEWLINE_xXActive, uncontrolled infectionsXx_NEWLINE_xXNo active infections requiring systemic antibioticsXx_NEWLINE_xXAny sign of active uncontrolled disease including but not restricted to cardiac disease, infections, hepatitis; any severe chronic disease potentially interfering with the protocol including human immunodeficiency virus (HIV) infection, active hepatitis B or C; it includes major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study periodXx_NEWLINE_xXActive uncontrolled systemic infections (defined as infections causing fevers and infections requiring intravenous antibiotics when intravenous antibiotics have been administered for less than 72 hours), active coagulation disorders or other major uncontrolled medical illnesses of the cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or immune system, history of myocardial infarction, history of ventricular tachycardia or ventricular fibrillation, active cardiac arrhythmias (active atrial fibrillation is not allowed, resolved atrial fibrillation not requiring current treatment is allowed [anticoagulants count as current treatment]), active obstructive or restrictive pulmonary disease, active autoimmune diseases such as rheumatoid arthritisXx_NEWLINE_xXNew or active infection as determined by fever, unexplained pulmonary infiltrate or sinusitis on radiographic assessment; infections diagnosed within 4 weeks of registration must be determined to be controlled or resolving prior to treatmentXx_NEWLINE_xXPatients with active systemic infections requiring intravenous antibiotics, coagulation disorders, or other major medical illness of the cardiovascular, respiratory or immune system, which in the opinion of the PI or treating co-investigator is not acceptable risk for ACT, are excludedXx_NEWLINE_xXAbsence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.Xx_NEWLINE_xXActive clinically serious infections (> CTCAE grade 2)Xx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXActive HBV or HCV infections requiring therapy.Xx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXKnown active infections or oral temperature > 38.2 Celsius (C) fewer than 72 hours prior to receiving study treatment or systemic infection requiring chronic maintenance or suppressive therapyXx_NEWLINE_xXSubjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entryXx_NEWLINE_xXPHASE I: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections)Xx_NEWLINE_xXPHASE II: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections)Xx_NEWLINE_xXPresence of an infection including ulcerations and fungal infections in the breast to be studiedXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illness that are uncontrolled or the control of which may be jeopardized by this therapyXx_NEWLINE_xXActive infections requiring therapy, including HIV, hepatitisXx_NEWLINE_xXActive systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system; PI or his designee shall make the final determination regarding appropriateness of enrollmentXx_NEWLINE_xXAny active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, such as abnormal stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease; PI or his designee shall make the final determination regarding appropriateness of enrollmentXx_NEWLINE_xXActive known clinically serious infectionsXx_NEWLINE_xXPatients with other uncontrolled infections (except HIV/AIDS); for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infectionXx_NEWLINE_xXEvidence of active infectionsXx_NEWLINE_xXADDITIONAL CRITERIA FOR STUDY CONTINUATION: Evidence of active infectionsXx_NEWLINE_xXPatients with uncontrolled active infections (fever >= 38 degrees Celsius [C], septic shock)Xx_NEWLINE_xXSerious concomitant systemic disorders (including active infections or chronic infection requiring suppressive antibiotics) that would compromise the safety of the patient or compromise the patient’s ability to complete the study, at the discretion of the investigatorXx_NEWLINE_xXPatients with multiple viral infections including AdV are eligible if their AdV infection is persistent despite standard therapy as defined above. Patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enroll.Xx_NEWLINE_xXPatients with other uncontrolled/progressing infections defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.Xx_NEWLINE_xXPatients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:Xx_NEWLINE_xXAny coexisting medical condition that in the judgment of the treating physician is likely to interfere with study procedures or results including uncontrolled severe infections, as well as uncontrolled cardiac disease, or other organ dysfunction; patients with history of tuberculosis, human immunodeficiency virus (HIV) or hepatitis B and C are excludedXx_NEWLINE_xXUncontrolled infectionsXx_NEWLINE_xXPatients with other uncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infection; patients with ongoing viral infections are excludedXx_NEWLINE_xXPatients with other uncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to generating CTLs; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to generating CTLs; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infectionXx_NEWLINE_xXAbsence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.Xx_NEWLINE_xXPatients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatmentXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXPatients with active, uncontrolled infectionsXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXPatients with multiple CMV, EBV, adenovirus, HHV6 and BK virus infections are eligible given that each infection is persistent despite standard therapy; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enrollXx_NEWLINE_xXPatients with other uncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment\r\n* Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infectionXx_NEWLINE_xXPatients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolvedXx_NEWLINE_xXPatients with systemic infections and/or organ dysfunction mandating a reduced intensity conditioning regimen are also excludedXx_NEWLINE_xXActive systemic infections, coagulation disorders, or other major medical illnesses precluding major surgeryXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other major medical illnessesXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system; PI or his designee shall make the final determination regarding appropriateness of enrollment (Turnstile I)Xx_NEWLINE_xXAny active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, such as abnormal stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease; PI or his designee shall make the final determination regarding appropriateness of enrollment (Turnstile II)Xx_NEWLINE_xXHave active, acute, or chronic clinically significant infections.Xx_NEWLINE_xXUncontrolled infections; principal investigator (PI) is the final arbiter of this criterionXx_NEWLINE_xXPatients who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entry; patients with bacteremia must have documented negative blood cultures prior to study entryXx_NEWLINE_xXPatients with untreated positive blood cultures or progressive infections as assessed by radiographic studiesXx_NEWLINE_xXActive Mycobacteria, Histoplasma Capsulatum, Shigella, Salmonella, Campylobacter and Leishmania infections.Xx_NEWLINE_xXPatients who have uncontrolled systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular or respiratory systemsXx_NEWLINE_xXIndividuals with severe or uncontrolled recurrent cutaneous infections who are considered at elevated risk for serious infection on anakinra therapy will be excluded per physician discretionXx_NEWLINE_xXActive and uncontrolled infectionsXx_NEWLINE_xXActive systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system; PI or his designee shall make the final determination regarding appropriateness of enrollment (Turnstile I)Xx_NEWLINE_xXAny active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, such as abnormal stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary disease; PI or his designee shall make the final determination regarding appropriateness of enrollment (Turnstile II)Xx_NEWLINE_xXPatients with untreated or uncontrolled infectionsXx_NEWLINE_xXNo uncontrolled infections as determined by the investigatorXx_NEWLINE_xXPatients with active infections requiring specific anti-infective therapy are not eligible until all signs of infections are resolvedXx_NEWLINE_xXActive systemic infections (requiring anti-infective treatment), coagulation disorders, or any other active or uncompensated major medical illnessesXx_NEWLINE_xXPatients with active bacterial infections with systemic manifestations (malaise, fever, leucocytosis) are not eligible until completion of appropriate therapy.Xx_NEWLINE_xXRecent or ongoing serious infections within 2 weeksXx_NEWLINE_xXPatients with uncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic antifungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infectionXx_NEWLINE_xXDOCK8 deficiency with the two criteria listed below:\r\n* Clinical history of one or more episodes of life-threatening or severely disfiguring infection with opportunistic organisms, including severe recurrent cutaneous and sinopulmonary infections with bacterial or fungal infection, or viral infections with herpes simplex, herpes zoster, Molluscum contagiosum, or human papilloma virus\r\n* Homozygous or compound heterozygous mutations in the DOCK8 gene performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratoryXx_NEWLINE_xXHAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infectionsXx_NEWLINE_xXActive serious infections not controlled by antibioticsXx_NEWLINE_xXEvidence of active infectionsXx_NEWLINE_xXPatients with serious uncontrolled infections will not be eligibleXx_NEWLINE_xXPatients with serious uncontrolled infections at the time of planned transplant will be excludedXx_NEWLINE_xXAny active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, such as abnormal stress test and/or abnormal PFT; PI or designee shall make the final determination regarding appropriateness of enrollment (Turnstile II - Chemotherapy/Cell Infusion Exclusion Criteria)Xx_NEWLINE_xXActive serious infections not controlled by antibioticsXx_NEWLINE_xXKnown infections:Xx_NEWLINE_xXUncontrolled infections not responding to antimicrobial therapy or requiring intensive critical care or vasopressorsXx_NEWLINE_xXSerious concomitant systemic disorders (including active infections) that would compromise the safety of the patient or compromise the patient’s ability to complete the study, at the discretion of the investigator, including active autoimmune disease requiring treatment within the past 30 daysXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).Xx_NEWLINE_xXSubject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.Xx_NEWLINE_xXHas uncontrolled active infection of any kind. (Patients with infections controlled by active antibiotic treatment are eligible).Xx_NEWLINE_xXActive and uncontrolled systemic infections.Xx_NEWLINE_xXHistry of significant chronic or recurrent infections requiring treatmentXx_NEWLINE_xXConcurrent serious infections (i.e., requiring an intravenous antibiotic)Xx_NEWLINE_xXSubjects must have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, not have a significant active concurrent medical illness precluding protocol treatment or survivalXx_NEWLINE_xXAcute or chronic infections requiring systemic therapy, including, among others:Xx_NEWLINE_xXActive clinically serious infections (? CTCAE v4.03 Grade 2).Xx_NEWLINE_xXHIV infection, active hepatitis B or C infection. History of treated hepatitis B or C is permitted if the viral load is undetectable. HCC patients with controlled or chronic stable HBV infection will be eligible for screening. HCC patients with HBV infections who are not on anti-HBV treatment will be excluded from the study. HCC subjects with HCV infections will be allowed for screening; however, subjects with both HBV and HCV infections will be excluded for screeningXx_NEWLINE_xXActive infectionsXx_NEWLINE_xXConcurrent vaginal, vulvar, anal lesions or symptomatic infectionsXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or any other active major medical illnessesXx_NEWLINE_xXSevere infections =< 4 weeks prior to registration, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumoniaXx_NEWLINE_xXPatients with active infections or oral temperature > 38.2 Celsius (C) within 72 hours of leukapheresis. The procedure may be deferred.Xx_NEWLINE_xXViral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical useXx_NEWLINE_xXViral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an anti-herpetic drug, other than intermittent topical use (e.g., acyclovir)Xx_NEWLINE_xXInfections:\r\n* Known active current or history of recurrent bacterial, viral, fungal, parasitic, mycobacterial or other opportunistic infections (including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds)\r\n* Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to enrollment\r\n* History of tuberculosis or positive PPD without anti-mycobacterial therapy and/or active tuberculosis (TB) requiring treatment within the previous 3 years; subjects treated for tuberculosis with no recurrence in 3 years are permitted\r\n* Human immunodeficiency virus (HIV) positive, hepatitis B surface antigen or core antibody positive, hepatitis C infections (current or past), active Epstein-Barr virus infection\r\n* History of 2 or more episodes of cellulitis within the past 12 months\r\n* History of recurrent herpes simplex infections requiring suppressive antiviral therapy\r\n* History of invasive pulmonary infections, including candidiasis, aspergillosis, coccidioidomycosis and pneumocystis jirovecii\r\n* History of recurring or chronic infectionXx_NEWLINE_xXSubjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entryXx_NEWLINE_xXUncontrolled infections not responsive to antimicrobial therapy requiring intensive critical careXx_NEWLINE_xXAcute/chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy =< 12 weeks prior to registrationXx_NEWLINE_xXDONOR: Current serious systemic illness including uncontrolled infectionsXx_NEWLINE_xXCurrent uncontrolled infections.Xx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXActive clinically serious infections or other serious uncontrolled medical conditionsXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g., chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infections etc.)Xx_NEWLINE_xXActive systemic infections (defined as infections causing fevers or requiring anti-microbial treatment), active coagulation disorders or other major uncontrolled medical illnesses of the cardiovascular, respiratory, endocrine, renal, gastrointestinal, genitourinary or immune system, history of myocardial infarction, active cardiac arrhythmias, active obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXActive infections or oral temperature > 38.2º Celsius (C) within 48 hours of study entryXx_NEWLINE_xXUncontrolled infectionsXx_NEWLINE_xXActive bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapyXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXActive systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infections.Xx_NEWLINE_xXPatients with active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illness of the cardiovascular, respiratory or immune system, which in the opinion of the PI or treating co-investigator is not acceptable risk for ACT, are excludedXx_NEWLINE_xXPatients with active systemic infections requiring intravenous antibiotics, coagulation disorders or other major medical illness of the cardiovascular, respiratory or immune system, which in the opinion of the PI or treating co-investigator is not acceptable risk for ACT, are excludedXx_NEWLINE_xXSubjects must have recovered from major infections and/or surgical procedures and, in\n             the opinion of the investigator, not have a significant active concurrent medical\n             illness precluding protocol treatment.Xx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infectionsXx_NEWLINE_xXSerious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligibleXx_NEWLINE_xXPatients with serious uncontrolled infections at the time of transplant will be excludedXx_NEWLINE_xXThey have active infections such as hepatitis or fungal infections.Xx_NEWLINE_xXPatients with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.Xx_NEWLINE_xXSignificant acute or chronic infectionsXx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXPoor medical risk because of systemic diseases (e.g. active uncontrolled infections) in addition to the qualifying disease under study.Xx_NEWLINE_xXActive, unresolved infectionsXx_NEWLINE_xXOther concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness, uncontrolled infections, uncontrolled diabetesXx_NEWLINE_xXHistory of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.Xx_NEWLINE_xXAcute infections requiring parenteral therapyXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.)Xx_NEWLINE_xXFungal infections with radiological progression after receipt of amphotericin product or active triazole for > 1 monthXx_NEWLINE_xXSevere infections at the time of randomizationXx_NEWLINE_xXrequired parenteral antimicrobial therapy for active, intercurrent infectionsXx_NEWLINE_xXHave active, acute, or chronic clinically significant infections or bleeding within the last 6 months or previous thromboembolic or hemorrhagic events during anti angiogenic therapy.Xx_NEWLINE_xXActive uncontrolled infectionsXx_NEWLINE_xXKnown systemic infections including, but not limited to hepatitis B or C, or HIVXx_NEWLINE_xXFungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 monthXx_NEWLINE_xXAll infections must be resolved and the patient must remain afebrile for seven days without antibiotics prior to being placed on studyXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illness that are uncontrolled or the control of which may be jeopardized by this therapyXx_NEWLINE_xXActive serious infections in particular if requiring systemic antibiotic or antimicrobial therapyXx_NEWLINE_xXPatients with known systemic infections requiring antibiotics or chronic maintenance/suppressive therapyXx_NEWLINE_xXActive clinically serious infections (> grade 2)Xx_NEWLINE_xXPatients with systemic infections requiring active therapy within 72 hours of lymphodepletionXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)Xx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical conditions that would, in the investigator’s judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.); hepatitis testing at screening is not mandatory, but may be done per investigator discretionXx_NEWLINE_xXPatients with active systemic infections requiring antibiotics or active hepatitis A, B, or C.Xx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infections (not responding to antibiotics), including acute pelvic inflammatory diseaseXx_NEWLINE_xXPatient has any other concurrent severe and/or uncontrolled medical condition that would, in the investigator’s judgment, may cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol (e.g. chronic pancreatitis, chronic active hepatitis, active untreated or uncontrolled fungal, bacterial or viral infections, etc.).Xx_NEWLINE_xXActive serious infections in particular if requiring systemic antibiotic or antimicrobial therapyXx_NEWLINE_xXNo active infections requiring systemic therapyXx_NEWLINE_xXNo active serious infections in particular if requiring systemic antibiotic or antimicrobial therapyXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).Xx_NEWLINE_xXHistory of recurrent bacterial infections unrelated to hepatocellular carcinoma (HCC) (particularly skin or lung)Xx_NEWLINE_xXHistory of, or presently active or chronic viral infections (i.e. zoster or hepatitis)Xx_NEWLINE_xXActive clinically serious infections > CTCAE Grade 2Xx_NEWLINE_xXEvidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIVXx_NEWLINE_xXSubjects with signs or symptoms of other major diseases including, but not limited to: end organ failure, major chronic illnesses other than cancer, coagulation disorders, hemolytic conditions (eg, sickle cell disease ) or active infections that, in the opinion of the investigator, make it undesirable for the subject to participate in the study.Xx_NEWLINE_xXSevere infections within 4 weeks prior to randomizationXx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infections requiring intravenous antibioticsXx_NEWLINE_xXEvidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.Xx_NEWLINE_xXInfections such as pneumonia or wound infections that would preclude protocol therapyXx_NEWLINE_xXEvidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.Xx_NEWLINE_xXPatients must have recovered from any major infections and/or surgical procedures and, in the opinion of the investigator, not have significant active medical illness precluding protocol treatment or survivalXx_NEWLINE_xXActive clinically serious infectionsXx_NEWLINE_xXInfections or intercurrent illness requiring active therapyXx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infections hepatitisXx_NEWLINE_xXOther active serious illnesses (e.g., serious infections requiring antibiotics).Xx_NEWLINE_xXOther concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness, uncontrolled infections, uncontrolled diabetes, or known infection with HIVXx_NEWLINE_xXPatients who have active infections requiring therapy.Xx_NEWLINE_xXSerious concurrent medical illnesses (including uncontrolled major cardiac, pulmonary, Child-Pugh C liver or psychiatric diseases) or active major infections (including human immunodeficiency virus [HIV], hepatitis A-C)Xx_NEWLINE_xXSubjects with clinically serious infections requiring ongoing antibiotic therapyXx_NEWLINE_xXRecent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drugXx_NEWLINE_xXPatients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have significant active concurrent medical illnesses precluding study treatmentXx_NEWLINE_xXActive infection at initiation of study; recent infections requiring systemic treatment need to have completed therapy > 14 days before the first dose of study drugXx_NEWLINE_xXSubjects who have uncontrolled infection are not eligible; patients must have any active infections under control; fungal disease must be stable for at least 2 weeks before study entryXx_NEWLINE_xXKnown HIV-positive patients and those with other acquired/inherited immunodeficiencies are ineligible due to the possibility of affecting the response to indoximod and the higher risk of active opportunistic infections.Xx_NEWLINE_xXAny evidence of serious active infectionsXx_NEWLINE_xXConcurrent serious uncontrolled infections requiring treatment or known infection with HIVXx_NEWLINE_xXSevere systemic diseases or active uncontrolled illnesses.Xx_NEWLINE_xXNew or active infection as determined by fever, unexplained pulmonary infiltrate or sinusitis on radiographic assessment; infections diagnosed within 4 weeks of registration must be determined to be controlled or resolving prior to treatmentXx_NEWLINE_xXAbsence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.Xx_NEWLINE_xXRecovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).Xx_NEWLINE_xXSevere infections necessitating use of antibiotics / antivirals during the screening periodXx_NEWLINE_xXUncontrolled infectionsXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illnesses that are uncontrolledXx_NEWLINE_xXPatients must not have any active infectionsXx_NEWLINE_xXSerious, active infections must be controlled; patients may be enrolled while still on antibiotics as long as clinical signs of active infection are absentXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXPatients with severe systemic infectionsXx_NEWLINE_xXUncontrolled systemic disease like active infectionsXx_NEWLINE_xXActive serious infections not controlled by antibioticsXx_NEWLINE_xXActive hepatitis or other active infectionsXx_NEWLINE_xXPatients with active clinical infectionsXx_NEWLINE_xXActive infections not responding to therapy; all efforts should be made to clear the infection prior to enrollmentXx_NEWLINE_xXKnown active infectionsXx_NEWLINE_xXFungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 monthXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnessesXx_NEWLINE_xXActive viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.Xx_NEWLINE_xXSignificant acute or chronic infections, including:Xx_NEWLINE_xXPatients with active infections requiring systemic treatment.Xx_NEWLINE_xXc. Active or failed to control serious infections (CTCAE version 4.03 > grade 2 infections)Xx_NEWLINE_xXKnown active infectionsXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive infections requiring systemic antibiotics.Xx_NEWLINE_xXActive infections requiring systemic antibiotics.Xx_NEWLINE_xXcertain heart problems, active or chronic infections, serious significant diseases, AIHA requiring treatment, other current cancer or within last 5 yearsXx_NEWLINE_xXPatients with acute infections (viral, bacterial or fungal infections requiring therapy)Xx_NEWLINE_xXActive clinically serious infections (i.e. patients currently taking antibiotics)( Grade 2 NCI-CTC Version 3.0)Xx_NEWLINE_xXKnown HIV and/or Hepatitis B or C infectionsXx_NEWLINE_xXDONOR: Current serious systemic illness including uncontrolled infectionsXx_NEWLINE_xXPatients must be free of active infections requiring antibiotics, with the exception of uncomplicated urinary tract infections (UTIs)Xx_NEWLINE_xXCurrent infections requiring antibiotic therapy.Xx_NEWLINE_xXAny evidence of serious active infections.Xx_NEWLINE_xXDONOR: No active or chronic infectionsXx_NEWLINE_xXClinically significant uncontrolled illness or active infectionsXx_NEWLINE_xXActive uncontrolled serious infection or sepsis at study enrollment; patients receiving antibiotics for infections that are under control may be included in the studyXx_NEWLINE_xXUncontrolled infections not responsive to antimicrobial therapy requiring intensive critical careXx_NEWLINE_xXUncontrolled life-threatening infectionsXx_NEWLINE_xXActive or uncontrolled infectionsXx_NEWLINE_xXPatients requiring intravenous (IV) antiviral or IV antibiotic treatment for ongoing infectionsXx_NEWLINE_xXSerious intercurrent infections or non-malignant medical illnesses that are uncontrolled or the control of which may be jeopardized by this therapyXx_NEWLINE_xXPatients requiring IV antiviral or IV antibiotic treatment for ongoing infectionsXx_NEWLINE_xXActive and uncontrolled infections, including hepatitis B or CXx_NEWLINE_xXActive systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXPatients must not have active uncontrolled infections, other medical or psychological/social conditions that might increase the likelihood of patient adverse effects or poor outcomesXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive infection requiring systemic treatment or any uncontrolled infections =< 14 days prior to enrollmentXx_NEWLINE_xX8. Any evidence of serious active infections.Xx_NEWLINE_xXPatients with active clinically serious infections defined as >= grade 2 according to NCI CTCAE, version 4.0Xx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders).Xx_NEWLINE_xXActive infections prior to receiving study treatment or systemic infection requiring chronic maintenance or suppressive therapyXx_NEWLINE_xXPatients with active infections, including HIV, will be excludedXx_NEWLINE_xXActive systemic infections, coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXSevere infections within 28 days prior to the first dose of study treatmentXx_NEWLINE_xXSevere intercurrent infectionsXx_NEWLINE_xXConcurrent serious infections requiring parenteral antibiotic therapy.Xx_NEWLINE_xXPatients with serious intercurrent infections, or nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of this therapyXx_NEWLINE_xXPatients with other uncontrolled/progressing infections defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.Xx_NEWLINE_xXAny evidence of serious active infectionsXx_NEWLINE_xXActive or chronic recurrent systemic infections that require continuous antimicrobial therapy during the Kevetrin study periodXx_NEWLINE_xXActive infections requiring antibioticsXx_NEWLINE_xXInfectionsXx_NEWLINE_xXPatients with systemic infections requiring antibiotics or chronic maintenance/suppressive therapyXx_NEWLINE_xXPatients with uncontrolled concurrent illness, active infection requiring i.v. antibiotics, or uncontrolled infections, or a fever > 38.5°C on the day of scheduled dosingXx_NEWLINE_xXActive systemic infections (for e.g.: requiring anti-infective treatment), coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXSerious, active infections must be controlled; patients may be enrolled while still on antibiotics as long as clinical signs of active infection have resolvedXx_NEWLINE_xXPatients with concurrent severe and/or uncontrolled medical co-morbidities - including active infections, unstable uncontrolled diabetes, cardiovascular and pulmonary, renal, psychiatric or social conditions that could compromise the safety or compliance of treatment are not eligible.Xx_NEWLINE_xXKnown active infection (except fungal nail infections).Xx_NEWLINE_xXPatients with multiple CMV, EBV or adenovirus infections are eligible given that each infection is persistent despite standard therapy as defined above; patients with multiple infections with one persistent infection and one controlled infection are eligible to enrollXx_NEWLINE_xXUncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollmentXx_NEWLINE_xXActive clinically serious infections of > Grade 2 and/or active infections that require treatment with systemic agentXx_NEWLINE_xXActive infections, including opportunistic infectionsXx_NEWLINE_xXSevere systemic infections, current or within the two weeks prior to initiation of AEB071.Xx_NEWLINE_xXActive (acute or chronic) or uncontrolled severe infectionsXx_NEWLINE_xXActive clinically serious infections defined as >= Grade 3 according to NCI CTCAEXx_NEWLINE_xXSevere systemic diseases or active uncontrolled infectionsXx_NEWLINE_xXHave active, acute, or chronic clinically significant infections or bleeding.Xx_NEWLINE_xXEvidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV.Xx_NEWLINE_xXRecent infections not meeting the criteria for severe infections within 2 weeks prior to Cycle 1, Day 1Xx_NEWLINE_xXParticipants who have active, uncontrolled infections.Xx_NEWLINE_xXPatients with important infections requiring antibiotics are INELIGIBLE, but patients who acquire minor infections while on the study may remain on the studyXx_NEWLINE_xXActive systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXOpportunistic infectionsXx_NEWLINE_xXPatients with active infections; the principal investigator (PI) is the final arbiter of the eligibilityXx_NEWLINE_xXActive clinically serious infections > Grade 2 (NCI-CTCAE Version 3.0)Xx_NEWLINE_xXKnown active infections requiring IV antibiotic, antiviral, or antifungal therapy.Xx_NEWLINE_xXSerious concurrent medical problems, uncontrolled infections, or disseminated intravascular coagulopathy (DIC), hepatic cirrhosis, or chronic kidney disease.Xx_NEWLINE_xXAcute infections (viral, bacterial or fungal infections requiring therapy).Xx_NEWLINE_xXPatients with active infections, including HIV, will be excluded, due to unknown effects DAC/THU on systemic immunityXx_NEWLINE_xXOther serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders)Xx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXActive systemic infections (for e.g.: requiring anti-infective treatment), coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, as evidenced by a positive stress thallium or comparable test, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXActive systemic infections (e.g.: requiring anti-infective treatment), coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive or restrictive pulmonary diseaseXx_NEWLINE_xXConcurrent opportunistic infectionsXx_NEWLINE_xXPatients with active systemic infections requiring antibiotics or chronic maintenance/suppressive therapy; once the infection in question has resolved and patient is off antimicrobial treatment, patients may participateXx_NEWLINE_xXUncontrolled (not being treated) infections at the time of cytoreductionXx_NEWLINE_xXPatients with opportunistic viral infections other than CMVXx_NEWLINE_xXSepsis and/or acute, chronic, or ongoing infections that are currently being treated with systemic antimicrobialsXx_NEWLINE_xXSubjects with active uncontrolled infection or who are human immunodeficiency virus (HIV) positive (subjects with acute infections requiring treatment should delay screening/enrollment until the course of therapy has been completed and the event is considered controlled)Xx_NEWLINE_xXUncontrolled infections that are not responsive to antimicrobial therapyXx_NEWLINE_xXLocal skin infections at or near the acupuncture sites or are under treatment for active systemic infectionXx_NEWLINE_xXSevere infections within 4 weeks prior to Day 1Xx_NEWLINE_xXActive clinically serious infections of > Grade 2Xx_NEWLINE_xXActive serious infections uncontrolled by antibioticsXx_NEWLINE_xXPatients who have uncontrolled systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular or respiratory systems.Xx_NEWLINE_xXPatients with any active hepatitis infections.Xx_NEWLINE_xXAcute treatment for an infection (excluding fungal infection of the skin and sexually transmitted infections) or other serious medical illness within 2 weeks before Segment B enrollmentXx_NEWLINE_xXLocal skin infections at or near the acupuncture sites or active systemic infectionXx_NEWLINE_xXPatients must have no evidence of active infections at the time of transplantationXx_NEWLINE_xXThere must be no uncontrolled active infections or medical conditions that the investigator feels will compromise the safety of the treatment and/or the assessment of the efficacy of therapyXx_NEWLINE_xXPatient with active infectionsXx_NEWLINE_xXActive and uncontrolled infectionsXx_NEWLINE_xXTreatment may be given to eligible patients with a single or multiple infections; patients with multiple infections with one or more reactivation and one or more controlled infection are eligible to enrollXx_NEWLINE_xXPatients with other uncontrolled infections; for bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment; for fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment; progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection; persisting fever without other signs or symptoms will not be interpreted as progressing infectionXx_NEWLINE_xXPatients with uncontrolled infectionsXx_NEWLINE_xXPatients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatmentXx_NEWLINE_xXActive uncontrolled bacterial, fungal, or viral infections – all prior infections must have resolved following optimal therapyXx_NEWLINE_xXPatients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatmentXx_NEWLINE_xXActive infections requiring systemic therapyXx_NEWLINE_xXActive infection requiring antimicrobial treatment that would interfere with interpretation of adverse events, cutaneous reactions or efficacy. Treatment of minor concurrent infections should be limited to less than 10 days.Xx_NEWLINE_xXEvidence of severe pulmonary infections, as judged by the investigatorXx_NEWLINE_xXPatients with ongoing symptomatic dental infectionsXx_NEWLINE_xXactive infections of the oral cavityXx_NEWLINE_xXActive infection (except mild upper respiratory infections)Xx_NEWLINE_xXUncontrolled intercurrent illness including, but not limited to active infectionsXx_NEWLINE_xXPatients with clinically significant active infectionsXx_NEWLINE_xXPatients with known active treatment for hepatitis B and C infectionsXx_NEWLINE_xXActive serious infections not controlled by antibioticsXx_NEWLINE_xXPatients with active urinary tract infectionsXx_NEWLINE_xXPatients should not have active infections or concurrent neoplastic disease except for skin cancerXx_NEWLINE_xXDocumented acute prostatitis or urinary tract infectionsXx_NEWLINE_xXAny serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease.Xx_NEWLINE_xXActive acute infection (i.e. currently treated with antibiotics); patients with chronic infections such as hepatitis B or C, mycobacterium avium or similar infections will be eligible provided they meet all other eligibility criteriaXx_NEWLINE_xXPatients with invasive fungal infectionsXx_NEWLINE_xXPatients with known active treatment for hepatitis B and C infectionsXx_NEWLINE_xXClinically active hepatitis A, B, or C infectionsXx_NEWLINE_xXSevere infections within 28 days prior to Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia or active tuberculosisXx_NEWLINE_xXActive infections of oral cavityXx_NEWLINE_xXPatients with active treatment for active hepatitis B and C infectionsXx_NEWLINE_xXPatients with active infections.Xx_NEWLINE_xXActive, uncontrolled infections within 7 days of study entry requiring systemic therapy.Xx_NEWLINE_xX